Cost-effectiveness of Interferon Gamma Release Assay (QFT-IT) as a Diagnostic Test for Intraocular Tuberculosis by Chen, Shu
Cost-effectiveness of Interferon Gamma Release Assay (QFT-IT) as a 
Diagnostic Test for Intraocular Tuberculosis 
 
by 
Shu Chen 
Duke Global Health Institute 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Eric Finkelstein, Supervisor 
 
___________________________ 
Shenglan Tang 
 
___________________________ 
Jan Ostermann 
 
Thesis submitted in partial fulfillment of 
the requirements for the degree of Master of Science in the Duke Global 
Health Institute in the Graduate School 
of Duke University 
 
2014 
 
 
 
 
  
ABSTRACT 
Cost-effectiveness of Interferon Gamma Release Assay (QFT-IT) as a 
Diagnostic Test for Intraocular Tuberculosis 
by 
Shu Chen 
Duke Global Health Institute 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Eric Finkelstein, Supervisor 
 
___________________________ 
Shenglan Tang 
 
___________________________ 
Jan Ostermann 
 
An abstract of a thesis submitted in partial 
fulfillment of the requirements for the degree 
of Master of Science in the Duke Global 
Health Institute in the Graduate School of 
Duke University 
 
2014 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Shu Chen 
2014 
 
 iv 
 
Abstract: 
Background: 
Interferon Gamma Release Assays (IGRAs) have proven to be potential replacement of 
tuberculin skin test (TST) in screening and diagnosing tuberculosis as shown by previous 
health economic studies. Given that these studies all center on pulmonary tuberculosis, 
we sought to examine the cost-effectiveness of IGRAs, specifically QFT-IT, as a 
diagnostic test for intraocular tuberculosis among uveitis patients in Singapore.  
Method:  
A decision tree was constructed to evaluate the cost-effectiveness of the QFT-IT for 
diagnosing intraocular tuberculosis among uveitis patients over a 30-year horizon. The 
input data were based on a cohort of 102 patients who presented with symptoms of 
uveitis and underwent relevant treatment and follow-up visits from 2009 to 2010 at 
Singapore National Eye Center (SNEC). By calculating their incremental cost-
effectiveness ratio, we compared the cost-effectiveness of three strategies: TST alone, 
QFT-IT alone and TST followed by QFT-IT as a confirmatory test.  
Results: 
Our results show that in cost terms alone, QFT-IT alone strategy is the most expensive 
one (889 SGD per person), followed by TST alone (850 SGD per person) and finally the 
dual strategy (789 SGD per person). While examining effectiveness alone, TST alone 
strategy is the most effective one that helps gain 17.4923 quality-adjusted life years 
(QALYs) followed by QFT-IT alone and the dual strategy. Using the conventional 
willingness to pay of 50,000 USD/QALY (63000 SGD/QALY), having an incremental 
cost-effectiveness ratio of 1644 SGD/QALY demonstrates that TST alone strategy is the 
best choice to screen ocular TB in Singapore.  
Conclusion:  
Given the local ocular tuberculosis prevalence and key assumptions made in the analysis 
model, the TST alone strategy is recommended to diagnose intraocular TB among uveitis 
patients in Singapore. 
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1. Introduction: 
1.1 Burden of Disease 
 
Tuberculosis (TB) remains a major global health problem, which ranks as the second 
leading cause of death among infectious diseases after human immunodeficiency virus 
(HIV) (Global tuberculosis report, 2013). It was estimated that 8.6 million new TB cases 
and 1.3 million TB deaths occurred in 2012, which is unacceptably high given the 
preventability of the disease (Global tuberculosis report, 2013). TB is a gradually 
progressing granulomatous infectious disease caused by bacillus Mycobacterium 
tuberculosis, which usually affects the lungs (pulmonary TB).  However, it can affect 
other sites (extrapulmonary TB) in the body as well, including the cardiovascular system, 
gastrointestinal system, musculoskeletal system, genitourinary tract, central nervous 
system, skin and eyes (M, El-Asrar, Abouammoh, & Al-Mezaine, 2009). The 
extrapulmonary involvement may occur either simultaneously or independently from 
clinically apparent pulmonary TB.  
Intraocular TB mimics various uveitis infections, which is partially due to the similarity 
of infection site, the host response and the virulence of the organism (Gupta, Gupta, & 
Rao, 2007). Basically uveitis is inflammation inside the eye that affects uveal tract and 
adjacent structures and patients generally experience eye redness and irritation, blurred 
vision, ocular pain or even blindness, which severely affects their quality of life 
(Barisani-Asenbauer et al., 2012). Uveitis meets the criterion for classification as a rare 
disease with an estimated prevalence of around 38 cases per 100,000 people (Barisani-
Asenbauer, et al., 2012). Although it is rare and more common in younger people, it 
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ranks as the fourth most common cause of blindness among the working-age population 
in the developed world (Barisani-Asenbauer, et al., 2012).Steroids given as eye drops are 
considered as the standard treatment for uveitis. Among all the intraocular changes 
caused by Mycobacterium tuberculosis, posterior uveitis appears to be the most common 
clinical presentation followed by anterior uveitis, panuveitis and intermediate uveitis 
(Gupta, et al., 2007).  There exists no accurate estimate of the true prevalence of 
intraocular TB due to the lack of uniform diagnostic criteria and the difficulty of 
confirming the diagnosis by laboratory methods (M, et al., 2009). Generally, intraocular 
TB is much less common than pulmonary TB and the percentage of TB-associated uveitis 
among uveitis patients varies in regions and countries. For example, Wakabayashi et al 
found that in Japan among 189 referred uveitis patients, 6.9% were diagnosed with 
tuberculous uveitis (Wakabayashi, Morimura, Miyamoto, & Okada, 2003). The 
percentage was 4% in China according to a study by Abrahams and Jiang and 10.5% in 
Saudi Arabia (Abrahams & Jiang, 1986; Islam & Tabbara, 2002). A study in India found 
that tuberculosis only accounted for 0.39% of the 1,273 uveitis patients (Biswas, Narain, 
Das, & Ganesh, 1996).    
1.2 Diagnosis of Intraocular TB 
 
Due to the difficulty in obtaining microbiological evidence to confirm the presence of 
intraocular TB, diagnosis is presumptive and primarily based on clinical symptoms in 
almost all of the reported cases (Al-Mezaine, Al-Muammar, Kangave, & Abu El-Asrar, 
2008; Cimino, Herbort, Aldigeri, Salvarani, & Boiardi, 2009; Morimura et al., 2002; 
Rosen, Spalton, & Graham, 1990; Sakai, Matsuzawa, Usui, & Yano, 2001; Sheu et al., 
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2001; Wolfensberger, Piguet, & Herbort, 1999). In most studies, the diagnostic criteria 
for the presumptive ocular TB are: “1) ocular findings consistent with possible 
intraocular TB with no other cause of uveitis suggested by history of symptoms or 
ancillary testing; 2) strongly positive tuberculin skin test (TST) results (≥15 mm area of 
induration/necrosis); 3) response to antituberculous therapy with absence of recurrences” 
(M, et al., 2009).  Of the three diagnostic criteria, the positive result of TST, already used 
for about a century to screen TB, is regarded as one critical sign in making the diagnosis. 
Despite its widespread usage, TST is limited in its non-specific reactivity in persons 
vaccinated with BCG and infected with non-tubercular mycobacteria. Advances in 
molecular biology have resulted in the development of the Interferon Gamma Release 
Assays (IGRAs) that measure IFN-γ responses to TB-specific antigens. This newly 
introduced diagnostic test has been suggested as a replacement for TST (Nienhaus, 
Schablon, Costa, & Diel, 2011; Pooran et al., 2010). Currently there are two different 
commercially available IGRAs: the ELISA-based QuantiFERON Gold (QFT-G) or 
QuantiFERON Gold In-Tube (QFT-IT) of Cellestis, Australia and the T-SPOT-based T-
SPOT.TB of Oxford, UK.  
Many studies have observed a higher specificity of IGRAs but evidences remain 
conflicting in terms of their sensitivity compared with TST (Nienhaus, et al., 2011). 
Apart from higher specificity, IGRAs offer the additional advantage of not requiring 
patients to come back after 48-72 hours as TST does. The direct testing cost of IGRAs, 
however, is higher than TST, which necessitates the use of economic evaluation studies 
that compare the cost-effectiveness of TST and IGRAs in screening and diagnosing TB.   
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1.3  Literature review: 
 
1.3.1 Overall description of the analysis model  
 
Recent studies all focused on pulmonary TB to evaluate the cost-effectiveness of IGRAs. 
Nienhaus et al (2011) conducted a systematic review of cost-effectiveness studies that 
compared different TB-screening strategies. They only included studies that used Markov 
modelling to take into account the health transition from latent TB infections (LTBI) to 
active TB and time-varying treatment outcomes. In the eight included studies,  
participants were followed from two years to life-long and costs and effectiveness were 
discounted at a rate of 3%. All studies relied on incremental cost effectiveness ratio 
(ICER) to select the best testing strategy but differentiated in terms of the measurement 
of effectiveness. Six of the reviewed studies measured effectiveness using quality-
adjusted life years (QALYs) or life years gained (LYG) and the other two used active TB 
cases prevented due to lack of data. 
1.3.2 Summary of available evidence  
 
Evidences available shows inconsistency of the cost-effectiveness of different TB testing 
strategies: TST only, IGRA only, TST followed by an IGRA confirmatory test. Factors 
that contribute to the inconsistency include TB prevalence, the screening population, test 
and treatment costs, assumed sensitivity and specificity of the tests and the health 
financial constraint to gain a unit increase of effectiveness.   
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Seven out of the eight reviewed studies by Nienhaus et al (2011) compared the cost-
effectiveness of three strategies: IGRA only, TST only and the dual strategy. Regardless 
of differences in assumptions and baseline input values of key variables, results of six of 
out of the seven studies unanimously showed that TST only was the most expensive 
strategy to achieve one-unit gain of effectiveness, thus suggesting it be replaced by either 
of the two other strategies. The only exceptional study found out that TST was cost 
saving in close contacts who did not receive BCG vaccination after infancy (Oxlade et al 
2013), but for subjects from low-incidence countries the dual strategy was the optimal 
one. Four out of the seven studies found out that the dual strategy was the least expensive 
one to achiever per unit of effectiveness gain and others favored the IGRA only as the 
most cost-effective strategy. 
1.3.3 Detailed review of four representative studies 
 
In Canada, Marra et al analyzed the cost-effectiveness of three strategies: TST, QFT-G 
and TST+QFT-G for screening TB among contacts with active TB patients (Marra et al., 
2008). Given that the performance of QFT-G varied among different population, they 
stratified their study participants by ethnicity (foreign-born, non-aboriginal Canadian-
born and aboriginal) and BCG-vaccination status. They assumed that TST and QFT-G 
had the same sensitivity of 0.99; specificity of TST was higher than 0.99 in BCG-
unvaccinated group and that of QFT-G was 0.96. Using a 20-year Markov model and 
QALYs as the measurement of effectiveness, they found out that QFT-G was most cost-
effective among BCG-vaccinated contacts while least cost-effective if applied to all cases. 
TST alone-strategy, however, proved to be most cost-effective for all cases with an 
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incremental net monetary benefit of Canada $3.70 given the assumed high sensitivity and 
specificity. Therefore, they concluded that it might not be wise to completely replace 
TST with QFT-G before more evidences about the performance characteristics of QFT-G 
become available in Canada.    
In contrast, Kowada et al demonstrated that QFT-IT alone was the most cost-effective 
strategy to screen pulmonary TB in Japan where almost everyone was BCG vaccinated 
from infancy(Kowada et al., 2008). They conducted a similar study among a cohort of 
1000 immunocompetent 20-year-old close contacts of pulmonary tuberculosis patients. 
They assumed QFT sensitivity of 0.76 and specificity of 0.96 at baseline. As for TST, the 
sensitivity was assigned to be 0.71 while specificity was 0.15 for base case, 0.60 for 
BCG-vaccinated in older children and 0.98 for non-BCG-vaccinated population. 
Probability of having LTBI/TB infections was assumed to be 0.2 at baseline. Both direct 
costs including inpatient and outpatient costs and indirect costs arising from productivity 
loss were calculated. Set against such a background, they found out that QFT-IT alone 
was the dominant strategy: the least expensive (471.54 USD) and the most effective 
(28.1099 QALYs) option. TST alone strategy proved to be the dominated one with the 
highest cost and lowest effectiveness.  
Pooran et al (2010) analyzed the cost-effectiveness of five different scenarios: TST, 
TSPOT-TB, QFT-IT, TST+TSPOT-TB and TST+QFT-IT in the UK. They built a two-
year model to estimate costs and measured the effectiveness with active TB cases 
prevented. Both probabilities and costs data were obtained from published literature. 
They assumed a prevalence of LTBI at 30% and high sensitivity and specificity for both 
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IGRA and TST (IGRAs performed better than TST in both sensitivity and specificity). 
They also added branches of hepatitis incurred by anti-tuberculosis treatment in their 
decision tree. Results showed that QFT-IT was the most expensive strategy while the 
TST+QFT-IT was the least costly choice. In effectiveness terms alone, T-SPOT.TB alone 
strategy ranked first for preventing 3.70 cases for a cohort of 1,000 contacts over the 2 
year examination period, followed by QFT-IT alone (3.47 cases), TST alone (2.98 cases), 
TST+T-SPOT.TB (2.83 cases), and TST+QFT-IT (2.65 cases). Compared with no 
screening, they concluded that TST+TSPOT-TB was most cost-effective with the lowest 
incremental cost at ₤37,206/TB case avoided while TST alone was the least preferred one.  
A recent study conducted in Brazil showed that in the short run TST remained the most 
cost-effective strategy compared with QFT-G alone and the dual strategy(Steffen et al., 
2013). Their study was conducted in a hypothetical cohort of 1,000 immunocompetent 
35-year-old close contacts of TB cases who were followed for two years. Effectiveness 
was measured by new TB cases averted and cost data from the National Health System in 
Brazil. They assumed a baseline value of 0.35 for the prevalence of LTBI, 0.70 for QFT-
IT sensitivity, 0.95 for QFT-IT specificity, 0.77 for TST sensitivity and 0.59 for TST 
specificity. Their results demonstrated that QFT-IT was the most effective one in averting 
6.63 TB cases per 1,000 contacts, followed by TST alone (6.56 cases prevented) and the 
dual strategy (4.59 cases prevented). In the costs term alone, the dual strategy stood out 
as the most cost-saving one with 101,945 USD to screen and treat 1,000 contacts while 
the QFT-IT alone strategy was the most expensive one with 121,054 USD. However, 
final results show that the cost per averted TB case is lowest for TST alone strategy 
 8 
 
(16,021 USD) and highest for the dual strategy (22,211 USD). As a result, they 
concluded that TST alone was the most cost-effective strategy that prevented 1,837 new 
TB cases per year with a total cost of around 30 million USD based on the local LTBI/TB 
incidence.  
Based on conflicting evidences in different study settings (see Table 1 and 2 for the brief 
summary of the four representative studies), countries issue different guidelines in 
screening tests recommendations. The Center for Disease Control (CDC) in the US 
recommends TST alone as the first-line test and IGRA alone is preferred for patients who 
are BCG-vaccinated or who cannot return to the physician within 48-72 hours after being 
administered with TST(Mazurek et al., 2010). It is suggested that health care providers 
choose which test to administer based on individual circumstances but the dual test 
(IGRA as a confirmatory test following initial TST positive results) is not recommended. 
In contrast, the National Institute of Health and Clinical Excellence (NICE) in the UK 
recommends the dual test strategy to screen for TB (“Clinical diagnosis and 
management”, 2006).  
1.4 Hypothesis:  
 
Despite the positive results that demonstrate the cost-effectiveness of IGRAs in screening 
pulmonary TB, no study has been conducted to evaluate IGRAs in screening and 
diagnosing intraocular TB. To fill the gap, the present study based on the data from a 
cohort of 102 uveitis patients in Singapore to analyze the cost-effectiveness of the three 
strategies: TST alone, QFT-IT alone and TST followed by QFT-IT as a confirmatory test. 
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Given that almost everybody is BCG-vaccinated in Singapore, we hypothesized that the 
dual test was the most cost-saving strategy and the QFT-IT alone strategy was the most 
effective one in screening TB among uveitis patients in Singapore.   
Table 1A: Summary of the four representative studies 
 
Study 
period 
Study 
setting 
Study  
Population 
TB 
prevalence Strategies Results 
Marra et al 20 years Canada 
Close contacts of 
foreign0born, non-
aboriginal, 
Canadian-born and 
aboriginal TB cases 
 
0.10-0.11 
TST-only; 
QFT-G only; 
TST+QFT-G 
 
QFT-G most effective for BCG-
vaccinated contacts; TST most 
effective for all cases 
Kowada et al Lifetime Japan 
Close contacts: 
immunocompetent 
and BCG-vaccinated 
0.2 
QFT-only; 
TST-only; 
TSTQFT 
 
QFT only>TST+QFT>TST only 
Pooran et al 2 years UK Close contacts 0.3 
TST-only; 
T-SPOT.TB-
only; 
TST+T.SPOT; 
QFT-only; 
TST+QFT 
 
TST+T.SPOT TB>TST+QFT-
IT>T.SPOT TB only>QFT-IT 
only>TST 
Stefen et al 2 years Brazil Close contacts 0.35 
QFT-IT-only; 
TST-only; 
TST+QFT-IT 
TST>QFT-IT>TST+QFT-IT 
 
Table 1B: Summary of the baseline data of the test-specific variables in the four 
representative studies 
 
TST Sensitivity  IGRA Sensitivity  TST Specificity  IGRA Specificity  
Marra et al 
0.99 0.99 
>0.99  
(BCG unvaccinated) 
0.96 
Kowada et al 0.71 0.76 0.15 0.96 
Pooran et al 
0.85 
0.89 (QFT-IT);  
0.95 (T SOPT.TB) 
0.8 
0.95 (QFT-IT);  
1.00 (T SPOT.TB) 
Stefen et al 0.77 (>5 mm) 0.7 0.59 (>5mm) 0.95 
 
  
 10 
 
2. Methodology:  
2.1 Patients and Procedures: 
 
The input data were based on a two-year prospective cohort study among patients with 
new onset of uveitis at the Singapore National Eye Centre (SNEC) from January 1
st
, 2009 
to December, 31
st
, 2010. Patients presented with active uveitis at SNEC were recruited 
consecutively and they all underwent a full systemic check-up, ocular examination and 
standard baseline investigation after they consented to participate in the study. All 
patients were followed up for a minimum of one year after completing anti-TB treatment, 
or one year from initial recruitment if no treatment was given. Patients who did not 
complete follow-up, or who did not have one of the above tests, or who did not consent to 
participate were excluded from the study. Altogether 120 patients were enrolled into the 
study and 106 patients completed the follow-up.  Four out of the 106 patients did not 
have TST and therefore were excluded from this particular analysis. In the end a total 
number of 102 patients with a mean age of 48.2 were included into the final analysis. 
Ethical approval was obtained from the Singapore Health Services Centralized 
Institutional Review Board. The current study adhered to the tenets of the Declaration of 
Helsinki.  
Participants received both QFT-IT and TST tests. Blood was taken before TST was 
administered. Patients were referred to the Department of Infectious Disease at Singapore 
General Hospital (SGH) if they tested positive for either QFT-IT or TST. Every patient 
was prescribed with steroids (eye treatment) for uveitis and those tested positive for TB 
were given the option of initiating the standard nine-month anti-tuberculosis therapy 
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(ATT), specifically the isonicotinylhydrazine (INH) chemoprophylaxis, or not. Given the 
hepatotoxicity incurred by the INH chemoprophylaxis, liver function tests were 
performed in patients who initiated ATT at baseline, once a month for the first three 
months after starting ATT and once every three months for the rest six months of 
treatment. Patients diagnosed with hepatitis terminated ATT at once but still received eye 
treatment. Patients were followed up once a month for the first three months and three/six 
monthly thereafter if the eye symptoms remained active/inactive.  
2.2 Model Design: 
 
We built a decision tree using TreeAge Pro 2013 (TreeAge Software, Williamstown, MA) 
to analyze the cost-effectiveness of TST and QFT-IT as a diagnostic test of intraocular 
TB among patients presented with uveitis in Singapore. Currently TST remains the first-
line screening and diagnostic test for TB and is routinely administered among uveitis 
patients in clinical practice. In our model, three optional strategies were developed to 
compare the cost-effectiveness: 1) TST alone; 2) QFT-IT alone; 3) TST+QFT-IT. The 
decision trees of the three strategies are shown in Figure 1, Figure 2 and Figure 3 
respectively.  
We modeled four possible outcomes for the patients presenting with uveitis: 
asymptomatic, eye symptoms resolved, recurrent or persistent inflammation and death 
from hepatitis incurred by the ATT. As for patients whose uveitis is caused by 
tuberculosis, they were likely to end up in: 1) asymptomatic (if they consented to receive 
the ATT and got completely cured); 2) eye symptoms resolved (if they declined the ATT 
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but temporarily got cured by the eye treatment); 3) recurrent or persistent inflammation 
(if they received the ATT but it did not work or they declined the ATT and the eye 
treatment did not work either); 4) death from  hepatotoxicity due to ATT. For patients 
whose uveitis is irrelevant to tuberculosis, they might become asymptomatic if the eye 
treatment worked or ended up with recurrent inflammation if the eye treatment failed. 
Patients with the same outcome were assumed to share the same utilities regardless of the 
causality of their uveitis. 
The model is comprised of three stages: treatment period (four months of eye treatment 
or nine months of ATT), follow-up period and post-treatment period. It was extended to 
30 years to represent the remaining life expectancy of the patients given their mean age 
(48.2 years old) and the life expectancy of Singaporeans (80 for males and 85 for 
females). A discount rate of 3% was used to calculate the health-related quality of life 
(QoL) assuming that the health of all patients deteriorates at the same rate constantly and 
no other major health risk would occur in the post-treatment period. Besides, we also 
assumed a 100% return rate for TST reading and perfect medication adherence. Patients 
who refused TB treatment would not initiate it in the modeling 30 years. The impact of 
these assumptions was evaluated via sensitivity analysis. 
2.3 Model Inputs: 
 
All the input variables and sensitivity ranges were displayed in Table 2.  
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2.3.1 Probabilities:  
 
Probability inputs consist of test-specific and treatment-specific variables. The test-
specific probabilities were obtained from a to-be-published paper that examined the 
sensitivity and specificity of TST and IGRAs based on the same study cohort. Other 
probabilities such as the positive/negative predictive value and probability of 
positive/negative result were calculated based on prevalence, sensitivity and specificity at 
baseline. The TB prevalence among uveitis patients was calculated from the current study 
given its enormous variability in different countries as mentioned earlier. Five of the six 
treatment-specific probabilities were calculated using the data of the present study; the 
only one from the published literature was the probability of death incurred by the side 
effects of ATT since no death occurred in the present study.   
2.3.2 Cost: 
 
The total cost can be divided into three parts: test, treatment and follow-up consultations. 
All the cost data were calculated based on the current study (the discharge data from 
SNEC and SGH) except for the cost to patients who died from side effects of ATT. As 
Table 1 shows, the cost of having QFT-IT test was 156 Singapore dollars (SGD) while of 
TST was 22 SGD. The nine-month ATT cost 194 SGD in total. As the eye treatment 
costs varied moderately among patients, we calculated the individual costs first and then 
averaged them within the same treatment and outcome groups.  Considering the 
hepatotoxicity of ATT, patients who initiated ATT received six liver function tests during 
the nine-month treatment period, accounting for a total cost of 552 SGD.  
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The number of follow-up visits varied depending on the diagnosis and treatment that the 
patients received. Patients who tested positive were asked to visit both eye and infectious 
disease doctors while those who tested negative were only required to visit eye doctors. 
The frequency of infectious disease doctor visits was six times in nine months while that 
of eye doctor visits depended on the activity of the eye symptoms. Cost was not 
discounted for it was only a two-year study. 
2.3.3 Utilities: 
 
We used health-related QoL to measure the utilities of the patients. All the utility data 
were from published literature and all of them were measured by the EQ-5D instrument. 
The EQ-5D is a self-reported preference-based measure of general health status and 
covers questions on 5 dimensions: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. The scores range from -0.11 (worst possible health) to 1.0 (best 
possible health) (Fryback et al., 2007).  
It was assumed that patients at baseline had the same QoL and patients with the same 
prognosis shared the same QoL. Specifically, the QoL of patients at baseline was 0.80, of 
patients with persistent inflammation was 0.82, of TB uveitis patients with only eye 
symptoms resolved was 0.84 and of completely cured patients was 0.89 regardless of the 
etiology of their uveitis. Utilities were discounted at a rate of 3% and extended to 30 
years in the analysis model. 
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2.4 Sensitivity Analysis: 
 
The robustness of the baseline results was tested through one-way sensitivity and 
probabilistic analyses. For the sensitivity analyses, each parameter was varied within a 
reasonable range (based on literature values) to estimate its impact on the final results. 
For the probabilistic sensitivity analyses, we performed 10,000 iterations of Monte Carlo 
simulation and in each iteration a value was drawn from the assigned distribution of each 
variable. Thus, the cost-effectiveness estimates were calculated accordingly based on the 
10,000 repeated draws. In our model, the probabilities and utilities were assumed to 
follow beta distributions and costs were assumed to follow gamma distribution.  
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Figure 1 TST only strategy for diagnosis of presumed intraocular TB infection 
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Figure 2 IGRA only strategy for diagnosis of presumed intraocular TB infection   
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Figure 3 Dual strategy for diagnosis of presumed intraocular TB infection 
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Table 2 Probabilities and costs used in the base case and sensitivity analysis 
Variables  Baseline Value Range Sources 
TB prevalence among uveitis 
patients 0.225 0.2%-26.2% Calculated & (M, et al., 2009) 
TST sensitivity 0.69 0.64-0.95 
SNEC & (Ferrara et al., 2006; Huebner, Schein, & 
Bass, 1993; Lalvani et al., 2001; Meier, Eulenbruch, 
Wrighton-Smith, Enders, & Regnath, 2005) 
TST specificity 0.74 0.60-0.90 
SNEC&(Lee et al., 2006; Schwartzman & Menzies, 
2000) 
TST positive result 0.36   
TST PPV 0.44 
 
Calculated 
TST NPV 0.89 
 
Calculated 
QFT-IT sensitivity 0.64 0.60-0.95 SNEC & (Goletti et al., 2005; Ravn et al., 2005) 
QFT-IT specificity 0.995 0.900-0.999 SNEC & (Goletti, et al., 2005; Ravn, et al., 2005) 
QFT-IT positive result 0.15   
QFT-IT PPV 0.97 
 
Calculated 
QFT-IT NPV 0.90 
 
Calculated 
QFT-IT PPV given a positive TST 0.99  Calculated 
QFT-IT NPV given a positive TST 0.78  Calculated 
Probability of becoming 
asymptomatic for TB patients 0.909 0.73-1.00 Calculated 
Probability of becoming 
asymptomatic for non-TB patients 0.778 0.75-0.9 Calculated 
Probability of getting eye symptoms 
resolved for TB patients 0.600 0.55-0.65 Calculated 
Probability of starting INH 
treatment 0.437 0.423-0.514 Calculated 
Probability of having hepatitis 
incurred by INH 0.109 0.015-0.241 
(Bass et al., 1994; Salpeter, 1993; Smieja, Marchetti, 
Cook, & Smaill, 2000; Steele, Burk, & DesPrez, 1991; 
Taylor, 2000) 
Probability of dying from hepatitis 
incurred by INH 0.00002 0.00001-0.0001 (Salpeter, 1993; Salpeter & Salpeter, 2004) 
Cost of QFT-IT 156 20-200 SNEC & SGH(Nienhaus, et al., 2011) 
Cost of TST 22 10-160 SNEC & SGH(Nienhaus, et al., 2011) 
Cost for having TB treatment 
(having hepatitis ) asymptomatic 1054 - SNEC & SGH                            
Cost for having TB treatment 
(having hepatitis) persistent 
inflammation 1686 - SNEC & SGH 
Cost for having TB treatment (no 
hepatitis) asymptomatic 1752 
1636.52-
1814.31  SNEC & SGH 
Cost for having TB treatment (no 
hepatitis) persistent inflammation 2069 - SNEC & SGH 
Cost for not having TB treatment 
(no hepatitis) asymptomatic 525 505.09-612.59 SNEC & SGH 
Cost for not having TB treatment 
(no hepatitis) persistent 
inflammation 1071 625.64-1271.38 SNEC & SGH 
Cost for having TB treatment but 
dying from hepatitis 1258 - SNEC & SGH 
Baseline utility  0.8 0.66-0.95 (Frick et al., 2012) 
Patients end up in persistent 
inflammation 0.82 0.66-0.95 
(Frick, et al., 2012; Naik, Gries, Rentz, Kowalski, & 
Revicki, 2013) 
Patients end up in only eye 
symptoms resolved 0.84 0.7-0.98 (Frick, et al., 2012; Naik, et al., 2013) 
Patients end up in asymptomatic 0.89 0.88-0.90 (Bernert et al., 2009) 
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3. Results:    
3.1 Base case analysis: 
 
Table 3 shows the base case results of the cost-effectiveness of the three strategies as 
diagnostic tests for intraocular tuberculosis in Singapore. The cost is measured in 
Singapore dollars and the effectiveness is presented as QALYs, meaning the remaining 
life years after adjusting for QoL. The results demonstrate that both the total cost and 
QALYs are lowest for the dual strategy, with an average cost-effectiveness ratio of 
789/17.4552 SGD/QALYs. The TST alone strategy yields an incremental cost of 61 SGD 
as well as an incremental QALY gain of 0.0371 compared with the dual strategy. QFT-IT 
alone strategy proves to be the most expensive one and achieve intermediate QALY gains. 
A strategy is dominated if it has higher cost and lower effectiveness gains. In our study, 
the QFT-IT alone strategy is dominated by TST alone with an incremental cost-
effectiveness ratio (ICER) of -1980 SGD per QALY gained. Although the dual strategy 
has the lowest average cost-effectiveness ratio, it does not achieve as much QALYs gains 
as TST in this context. Given the conventional willingness to pay (WTP) of 63,000 SGD 
per QALY gained (50,000 USD/QALY: one US dollar equals to 1.26 Singapore dollars), 
our results (an ICER of 1644 SGD/QALY) recommend that conducting TST test alone is 
the optimal option to diagnose ocular TB in Singapore as it can help achieve most QALY 
gains within the assigned WTP threshold.   
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3.2 Sensitivity analysis: 
  
The one-way sensitivity analysis results reveal that the ICER of TST does not exceed the 
threshold of 63,000 SGD/QALY by varying any parameter within the assigned range. As 
reflected in the Tornado diagram in Figure 4, the major drivers of the change in ICER are: 
the QALYs for patients who end up with persistent inflammation, the intraocular TB 
prevalence among uveitis patients, the QALYs for patients who result in only eye 
symptoms resolved, the cost of QFT-IT test, the TST specificity and the probability of 
initiating ATT.  
See appendix for the detailed report of the one-way sensitivity analysis of the primary 
drivers. We observe an increasing trend of the ICER with the growth of QALYs for 
patients who end up with persistent inflammation and QALYs for patients who result in 
only eye symptoms resolved. The QFT-IT alone strategy remains to be the dominated one 
regardless of how the QALYs change. Tuberculosis prevalence among uveitis patients 
proves to be negatively associated with the ICER of TST alone strategy. The ICER 
decreases to 1467 SGD/QALY when the prevalence reaches to 26.2%. QFT-IT alone 
strategy still remains dominated when the prevalence is varied within the assigned range. 
The testing cost of QFT-IT turns out to be an important driver of the cost-effectiveness of 
QFT-IT alone strategy, which is not dominated until its cost surpasses 155 SGD. 
Nevertheless, having a lower QALYs gained renders QFT-IT alone a suboptimal strategy 
compared with TST alone. When varying the TST specificity from 0.60 to 0.90, the ICER 
of TST decreases from 4758 to 856 SGD/QALY. The QFT-IT alone strategy becomes 
more cost-saving than the TST alone when the TST specificity is as low as 0.60 but the 
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advantage vanishes after the TST specificity exceeds 0.675. A positive correlation is 
found between the probability of initiating TB treatment and the incremental cost of TST 
alone strategy, resulting in an increasing ICER of TST alone strategy as the probability 
climbs. The effectiveness gains for all the three strategy grow as more people are willing 
to initiate ATT.   
Figure 5 displays the cost effectiveness acceptability curve generated by the Monte Carlo 
simulation. It shows that TST alone strategy is cost-effective among 50% of iterations 
when the WTP is 3,300 SGD/QALY.  Once the WTP increases to 6,300 SGD/QALY, 
TST alone strategy becomes cost-effective among 100% of the iterations.  
 
Table 3: Cost-effectiveness of the three strategies as diagnostic tests for intraocular 
tuberculosis in Singapore  
Strategy Cost 
(SGD) 
Incremental 
cost (SGD) 
QALYs Incremental 
QALYs 
ICER  
(SGD/QALY) 
Dominance 
Dual  789 - 17.4552 - - Not dominated 
TST 850 61 17.4923 0.0371 1644 Not dominated 
QFT-IT 889 39 17.4726 -0.0197 -1980 Dominated 
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Figure 4 One-way sensitivity analysis: Tornado analysis output 
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Figure 5 Probabilistic sensitivity analysis: cost-effectiveness acceptability curve 
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Figure 6 The impact of the sensitivities on the optimality of each strategy 
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4. Discussion: 
  
The low specificity of TST in BCG-vaccinated and immunocompromised population 
necessitates the birth of IGRAs that can more specifically measure molecular responses 
to TB antigens. New technology often brings with new cost, making it necessary to 
evaluate whether the incurred cost is outweighed by increased effectiveness before 
widespread implementation. Results of previous studies recommended using either IGRA 
alone or dual strategy to replace the present TST alone strategy in screening and 
diagnosing pulmonary TB (Nienhaus, et al., 2011). Unlike the findings of most previous 
studies, the present incremental cost-effectiveness analysis demonstrates that performing 
single TST test to diagnose intraocular TB among uveitis patients is optimal in Singapore. 
In our analysis, the dual strategy, performing QFT-IT as the confirmatory test following a 
positive TST result, is the least costly one as it avoids unnecessary INH 
chemoprophylaxis by decreasing the number of false positive cases. QFT-IT alone 
strategy turns out to be the most expensive one and suboptimal in cost terms alone, thus 
rendering it to be dominated by TST alone strategy that helps to gain more QALYs and 
costs less. The advantage of the dual strategy in saving costs is offset by its comparative 
ineffectiveness measured by QALYs gained. Therefore, using the conventional WTP of 
63, 000 SGD per QALY gained, TST alone surpasses the dual strategy as the preferred 
choice for it gains more QALYs within the financial constraint. 
Interpretation and generalizability of the study results relies on specific key assumptions, 
the study setting and population. One key assumption in the present study is the lower 
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sensitivity of QFT-IT compared with TST, unlike most of the previous studies that 
assume QFT-IT outperforms, if not as good as, TST in terms of sensitivity (Nienhaus, et 
al., 2011; Oxlade, Pinto, Trajman, & Menzies, 2013). The mechanism behind QFT-IT 
test determines its higher specificity than TST especially among BCG-vaccinated and 
immunocompromised people, whereas the evidence remains conflicting in terms of their 
performance in sensitivity. For example, Mazurek et al found in their cross-sectional 
study of navy recruits that IGRAs might be less sensitive than TST given the negative 
QFT-G results for recruits born in high-prevalence countries and whose TST induration 
was ≥ 15mm(Mazurek et al., 2007). Pollock et al also raised serious concerns about the 
sensitivity of IGRA due to the extreme inconsistency between the results of their clinical 
diagnostic algorithm and the test outcome (Pollock et al., 2008). However, in a study 
among 54 patients with pulmonary TB disease, the sensitivity of QFT was found to be 81% 
compared with 78% for TST (Kang et al., 2005). Another study among a population of 
318 hospitalized patients found that the sensitivity of QFT was much greater than that of 
TST (67% vs. 33%)(Ferrara, et al., 2006). Given the inconsistent evidence and the 
different testing population in the present study, we obtained the test-related data from a 
local study, assuming TST had a sensitivity of 0.69, compared with 0.64 for QFT-IT. As 
a result, TST outperforms QFT-IT in screening out more true positives, resulting in more 
QALY gains to become the best option in diagnosing TB in uveitis patients.  
The impact of the test-specific sensitivity assumption on the outcome is further explored 
through sensitivity analysis (See Figure 6 for how the optimality of each strategy changes 
with the variance of sensitivity of the two tests). By varying the QFT-IT sensitivity from 
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0.60 to 0.95, QFT-IT alone transforms from a dominated strategy to the optimal choice 
once its sensitivity surpasses 0.87, holding TST sensitivity at the baseline level of 0.69. 
The QALYs gained for QFT-IT alone strategy reaches to 17.4995 when its sensitivity 
increases to 0.95, with an incremental effectiveness of 0.0073 compared with TST alone. 
Such findings suggest that TST may lose its advantage when QFT-IT sensitivity gets 
higher. Therefore, careful examination of the test performance in local setting and 
particular population is highly recommended for evaluation accuracy improvement. 
Another key assumption that favors the TST alone strategy is the 100% TST return rate, 
meaning nobody will miss the reading after 48-72 hours of the first skin test. It is true in 
Singapore where patient compliance and adherence is perfect but might not be the case in 
other study settings. For example, in the UK, up to 60% of patients fail to show up for 
TST readings (Bothamley et al., 2002; Dewan et al., 2006). In a study carried out in 
Brazil, 10% of the subjects failed to show up again for TST readings (Steffen, et al., 
2013). Failure to return significantly lowers the effectiveness of both TST alone and the 
dual strategy; however, the magnitude of the impact needs to be assessed based on the 
specific return rate in the study setting before recommending IGRAs for widespread 
adoption.     
Apart from the difference in key assumptions that gives rise to the inconsistency of 
results, it is noticeable that the present study population is uveitis patients rather than 
close contacts of pulmonary TB patients in most of the previous studies. In our study, all 
patients receive eye treatment regardless of the etiology of the uveitis. Unlike pulmonary 
TB patients whose symptoms are primarily relieved by ATT, intraocular TB patients 
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depend on both eye treatment (steroids) and ATT for full recovery. Thus, for false 
negatives who only receive eye treatment, there is a big chance that their eye symptoms 
will get resolved as well in the short run. The high efficacy of eye treatment minimizes 
the prognostic difference between true and false negatives, rendering the low specificity 
of TST less disadvantageous in this case.  
The huge gap between the testing cost of QFT-IT (156 SGD) and TST (22 SGD) in the 
present study is another contributor to the winning of TST alone strategy. The cost ratio 
of the two strategies is 7.09, significantly higher than previous studies which have the 
highest ratio of 5.6 (Nienhaus, et al., 2011). By varying the QFT-IT cost from 20 to 200 
SGD, we find out that QFT-IT alone outperforms TST as long as the QFT-IT testing cost 
remains lower than 155 SGD in cost terms alone. Although TST alone still stands out as 
the optimal choice with greatest QALYs gained based on the key assumptions mentioned 
above, QFT-IT alone is no longer dominated once the cost lowers down and might be 
recommended as the preferred strategy depending on how the assumptions change.   
Interestingly, we find that TST alone strategy can gain more QALYs compared with 
QFT-IT alone in Singapore where BCG vaccination is given to all the newborns since 
1957 ("Discontinuation of repeat," 2001). We assume a specificity of 0.995 for QFT-IT 
and 0.74 for TST at baseline. When varying the TST specificity from 0.60 to 0.90 in the 
one-way sensitivity analyses, TST outperforms QFT-IT with an incremental effectiveness 
of 0.028 QALYs even when its specificity decreases to 0.60. Such findings suggest that 
the higher specificity of IGRAs do not necessarily go with higher effectiveness gains 
even in BCG-vaccinated population. 
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We also observe the great impact of the probability of initiating ATT on the effectiveness 
gains of the three testing strategies. In our study, the probability of initiating ATT for 
uveitis patients who tested TB positive is 43.7%, compared with the widely used 
percentage of 80% among pulmonary TB positives (Taylor, 2000). The huge gap is 
largely attributed to the high expense of ATT in comparison to eye treatment alone which 
can also help relieve eye symptoms in the short run. The one-way sensitivity analysis 
observes a dramatic increase of effectiveness gains for all of the three strategies and the 
TST remains to be the optima strategy in saving 17.5809 QALYs with a cost of 1038 
SGD when the probability increases to 95%. It may suggest the need to promote ATT 
among uveitis patients who are tested TB positive to maximize the effectiveness gained.     
Our decision model assumes adherence of the nine-month INH treatment is perfect in 
Singapore, which might not be the case in other study settings. Adherence of the nine-
month ATT has always been an important concern as shown in previous studies. In a 
recent study conducted by Goswami et al among 496 adults who met the CDC guidelines 
for latent TB infection (LTBI), it is found that the completion rate is only 53% (Goswami 
et al., 2012). Low adherence will undoubtedly drive down the overall effectiveness of the 
three strategies, which might be necessary to model into the decision trees for a more 
comprehensive evaluation in settings where adherence is a concern.    
To our knowledge, the present study is the first one that compares the cost-effectiveness 
of the QFT-IT and TST in diagnosing TB among uveitis patients. Previous studies are all 
conducted among pulmonary TB patients for evaluation. Our findings recommend 
conducting TST single test in Singapore to diagnose ocular TB as it achieves the most 
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QALY gains given the financial threshold of 63,000 SGD/QALY. This is inconsistent 
with most of the findings of previous studies that recommend either QFT-IT alone or dual 
strategy to replace TST alone strategy (Nienhaus, et al., 2011). Causes for the 
inconsistency, as discussed previously, are different values assigned to test-specific 
parameters and assumptions made during modeling. For example, the NICE analysis, 
conducted in 2004, assumed that IGRAs had the same sensitivity with TST and only 
performed slightly better in terms of specificity (“Clinical diagnosis and management”, 
2006). Therefore, generalizability of the results of the present study substantially depends 
on the key assumptions made in the model. It is never too cautious to examine the 
assumptions when generalizing the results in another population.  
There are several limitations of the present study. In our model, we only calculated the 
direct treatment cost instead of including other relevant costs to patients. One prominent 
issue is the opportunity cost associated with the 72-hour waiting time when screened with 
TST. However, it is justifiable in the current study as we are evaluating cost from the 
perspective of Singaporean healthcare system. Studies that aim to evaluate the test from 
the patients’ perspective might need to include the cost in their modeling. Besides, we 
only calculated costs incurred during the two-year cohort study due to data availability, 
thus underestimating the future treatment costs especially for patients who end up with 
persistent inflammation. Although the two-year treatment cost has already demonstrated 
the tendency that patients with persistent inflammation spend more on treatment, it is still 
necessary to add estimated future cost into the model for optimized accuracy.  
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Our study used a static decision tree instead of a Markov model to estimate the cost 
effectiveness of the three testing strategies. The static framework assumes that the 
patients stick to the same eye status as that in or after the treatment for 30 years, 
underestimating the effectiveness gains of the nine-month INH chemoprophylaxis as the 
uveitis will come back to the TB patients who only receive eye treatment in a more 
frequent and severer manner in the long run.  
Further, that we applied 3% discounting rate to all patients regardless of their prognosis 
neglects the existing differential mortality between diagnosed and undiagnosed ocular TB 
patients, which also underestimates the effectiveness gains of the INH chemoprophylaxis. 
One ideal way to fix it is to calculate their QoL year by year to capture the effectiveness 
differentials. However, limited data availability prevents the current study from making it 
happen. Therefore, it might be an important area for future studies to measure the post-
treatment QoL changes among TB-associated and non-TB uveitis patients.  
In addition, our analysis did not sub-divide study participants according to their age 
group, immune status and ethnic groups. It is a challenge in the present study due to small 
sample size but can be an important area of future research.   
In conclusion, given the local prevalence and the key assumptions made in the analysis 
model, the TST alone strategy is recommended in diagnosing intraocular TB among, 
uveitis patients in Singapore.  
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Appendix  
Detailed report of the one-way sensitivity analyses results: the top six drivers 
1. QALYs of patients who end up with persistent inflammation 
 
2. Prevalence of intraocular TB among uveitis patients  
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3. QALYs of patients who result in only eye symptoms resolved 
 
4. QFT-IT testing cost 
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5. TST specificity 
 
6. Probability of initiating ATT 
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